IceCure Medical Delivers Conference Call Investor Update Sept 2019
IceCure CEO, Eyal Shamir and CFO, Ronen Tsimerman update on IceCure progress in investor conference call, Sept 2019. Listen to the full conference call here.
IceCure Medical Forges Landmark Strategic Deal with Global Medical Company, Terumo Corporation
The exclusive distribution agreement, supported by Terumo’s strong commitment, will accelerate commercialization of its ProSense™ cryoablation system to treat breast cancer tumors in Japan and Singapore, pending regulatory approval. Read more
IceCure Receives Israeli AMAR Approval for Use of its Freezing Technology in Specific Indications, Following an Earlier General Approval
The AMAR approval allows for freezing of benign and malignant tumors including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands. This achievement comes hot on the back of the company receiving a Class 3 CPT code from the American Medical Association that enables providers to apply for reimbursement for procedures using cryoablation […]
ICECURE PLATINUM SPONSOR OF THE 20TH WORLD CONGRESS OF THE INTERNATIONAL SOCIETY OF CRYOSURGERY, SEPT 4-5, 2019.
Demonstrating our commitment to advance the treatment of cancer using cryosurgery, we are proud to be the Platinum sponsor of the 20th World Congress of the International Society of Cryosurgery: Sept 4-5, 2019, Haifa, Israel. With talks from top experts sharing their latest clinical findings using our ProSense™ system, come and visit the IceCure booth […]
IceCure Medical Announces New Category III CPT Code for Breast Cryoablation Therapy, Issued by the American Medical Association
New Category III CPT Code expected to support further adoption of minimally invasive cryoablation treatments for breast cancer. Learn more.
IceCure featured in the leading interventional oncology news outlet, Interventional News
IceCure’s landmark US clinical trial, ICE3, for nitrogen-based cryoablation of small, low-risk, early stage malignant breast tumors without subsequently removing them, featured in Interventional News. Cryoablation shows promise in treating low-risk breast cancers. “If the positive preliminary findings are maintained as the patients enrolled in the study continue to be monitored, that will serve as […]
IceCure presents promising results from first-ever Interventional Radiology study
Data presented at the European Association of Urology showed the ProSense™ system at 1-year follow-up was safe, effective and without serious adverse events for treating small kidney tumors. Read more >
IceCure featured in the leading news education publication, Healio
The promise of cryotherapy as an alternative treatment for a specific group of [patients with] breast cancer.” Kenneth Tomkovich MD, radiologist at Princeton Radiology and director of breast imaging and interventions at CentraState Medical Center in Freehold, New Jersey discusses the positive preliminary findings of the ICE3 clinical trials. Read more >